Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis

  title={Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis},
  author={Thomas Wehrum and L. Beume and O. Stich and I. Mader and M. M{\"a}urer and A. Czapliński and C. Weiller and S. Rauer},
  pages={e601 - e605}
Objective To report 3 patients with multiple sclerosis showing severe activation of disease during immunotherapy with alemtuzumab. Methods Retrospective case series. Results Patient 1, a 21-year-old woman, developed severe cognitive impairment, sight deterioration, severe gait ataxia, urinary retention, and extensive progression of cerebral lesion load, including new lesions that exhibited gadolinium ring enhancement and dominance of CD19/20-positive B lymphocytes, 6 months after induction of… Expand
18 Citations
Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients.
  • 2
Monoclonal Antibodies for Multiple Sclerosis: An Update
  • 10
Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
  • PDF
Different MRI patterns in MS worsening after stopping fingolimod
  • 4
  • PDF


An observational study of alemtuzumab following fingolimod for multiple sclerosis
  • 33
  • Highly Influential
  • PDF
B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
  • 180
  • PDF
Alemtuzumab: the advantages and challenges of a novel therapy in MS.
  • 41
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
  • 261
  • PDF
CT and MRI findings of intracranial lymphoma.
  • 87
Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy
  • 45
  • Highly Influential
Insights into the mechanisms of the therapeutic e ffi cacy of alemtuzumab inmultiple sclerosis
  • Neurology
  • 2014